Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orna Therapeutics
Biotech
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
Eli Lilly has become the latest Big Pharma to buy itself into a corner of the in vivo CAR-T space via the acquisition of Orna for up to $2.4 billion.
James Waldron
Feb 9, 2026 8:41am
FDA rocked by leadership shake-ups—Chutes & Ladders
Apr 4, 2025 8:30am
Vertex and Orna team up to develop new blood disorder treatments
Jan 7, 2025 7:00am
BIO, Seaport, Orna and more—Chutes & Ladders
Apr 12, 2024 8:30am
ReNAgade lays off 10% of staff 6 months after $300M series A
Dec 5, 2023 10:15am
New RNA biotech raises $300M in largest private round of 2023
May 23, 2023 6:30am
